Giiant Pharma: Funding, Investors & Team (Sep 2026)
Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.
Giiant Pharma has raised $11.2M across 1 funding round on record, the most recent an undisclosed round of $11.2M announced in May 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Giiant Pharma Company Profile and Key Stats
Latest funding round on record: May 2021.
Giiant Pharma Funding Rounds
Giiant Pharma Founders and Leadership Team
Contact details for the Giiant Pharma team: 1 of 1 has an email address on file.
Start 14-day free trial →Giiant Pharma Funding Compared to Other Biotechnology Startups
Giiant Pharma's latest round of $11.2M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Giiant Pharma in Biotechnology and Montréal
Companies Similar to Giiant Pharma
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
Giiant Pharma Funding FAQs
What does Giiant Pharma do?
Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.
How much funding has Giiant Pharma raised?
Giiant Pharma has raised $11.2M across 1 round on record. The most recent is an undisclosed round of $11.2M announced in May 2021.
When did Giiant Pharma last raise funding?
Giiant Pharma's most recent funding round on record is an undisclosed round of $11.2M, announced in May 2021.
Who is the CEO of Giiant Pharma?
Maxime Ranger is listed as CEO at Giiant Pharma.
Where is Giiant Pharma headquartered?
Giiant Pharma is based in Montréal, Quebec, Canada.
How many employees does Giiant Pharma have?
Giiant Pharma is in the 1-10 employee band.
How does Giiant Pharma's funding compare to other Biotechnology startups?
Giiant Pharma's latest round of $11.2M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Giiant Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Giiant Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.